- Upstream Bio is a clinical-stage company developing **Viraqita**, the only known antagonist of the TSLP receptor in clinical development, currently in Phase 2 for chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD).  **[2022626_2144370_0]** 
- The company recently released **Phase 2 data for CRSwNP**, demonstrating Viraqita's efficacy numerically meets or exceeds competitors (Tezepelumab, Dupilumab) with a compelling **q12-week dosing interval**.  **[2022626_2144370_0]** **[2022626_2144370_2]** 
- Viraqita's potency allows for potential dosing every **12 or 24 weeks**, which is being tested in clinical trials.  **[2022626_2144370_0]** 
- Data for the severe asthma program is anticipated in the **first quarter of next year** (Q1 2026).  **[2022626_2144370_0]** **[2022626_2144370_3]** 
- Upstream Bio is **funded through 2027** following a successful IPO last year, enabling continued clinical development and commercialization preparations.  **[2022626_2144370_0]**

Upstream Bio (UPB)